A Practical Guide to Quantitative Pharmacology in Drug Development

Uncategorized /

When to Use PopPK/PD, Exposure Response, PBPK, and QSP, and When Not To 1. Introduction: Why Quantitative Pharmacology Matters Model informed development has shifted from optional exploratory analysis to a central part of decision making. Most high value decisions such as target viability, mechanism plausibility, first in human (FIH) dose selection, Phase 2 dose justification, […]

A Practical Guide to Quantitative Pharmacology in Drug Development Read More »

Modeling & Simulation as Regulatory Evidence in the CTD: Practical Case Studies Across PopPK/PD, PBPK, E–R, and QSP

CTD-series /

Model-informed analyses are increasingly recognized by regulators and sponsors as credible evidence—especially when the question is clear, the model is verified for purpose, and uncertainties are transparent. This article reviews real submissions where M&S supported dose selection, regimen bridging, DDI labeling, pediatric dosing, and systems-level benefit–risk insight. Contents Introduction Case 1 — Exposure Bridging (Pembrolizumab

Modeling & Simulation as Regulatory Evidence in the CTD: Practical Case Studies Across PopPK/PD, PBPK, E–R, and QSP Read More »

Biosimilar Development in 2025: From Comparative Trials to Analytical Confidence

Drug Development Strategy /

A joint evolution in FDA and EMA guidance signals a paradigm shift toward efficiency, science, and patient access. 1. The Changing Landscape For nearly two decades, biosimilar development followed a familiar path: prove similarity through large, comparative efficacy studies against the reference product. These studies—costly, time-consuming, and often redundant—became the accepted norm. In 2025, both

Biosimilar Development in 2025: From Comparative Trials to Analytical Confidence Read More »

Quantitative Systems Pharmacology (QSP) in Clinical Development: When to Use It, What It Delivers, and How to Make It Regulatory-Ready

Modeling and Simulation /

Audience: biotech C-suites, program leaders, clinical pharmacology & modeling teams. Why QSP matters now Sponsors increasingly face decisions where empirical models alone (PopPK, exposure–response) are not enough—novel mechanisms, combinations, complex biology, and heterogeneous populations. Quantitative Systems Pharmacology (QSP) integrates disease/biology knowledge with pharmacology to generate testable, decision-grade predictions across the translational and clinical continuum (e.g.,

Quantitative Systems Pharmacology (QSP) in Clinical Development: When to Use It, What It Delivers, and How to Make It Regulatory-Ready Read More »

AI as a Scientific Partner: Where Large Language Models Really Fit in Drug Development

AI/ML /

By Aniruddha Amrite, ClinPharm Dev Solutions LLC Executive summary (for busy leaders) Large language models (LLMs) are already useful across the drug development continuum—if we anchor them to trusted sources and keep humans in the loop. Practical wins today include faster literature synthesis and hypothesis triage, eligibility criteria parsing and patient–trial matching at scale, drafting

AI as a Scientific Partner: Where Large Language Models Really Fit in Drug Development Read More »

The Regulatory Glue: Integrating Modules 2–5 for FDA, EMA, and Beyond

CTD-series /

Figure 1. Global “regulatory glue” overview: a shared evidence package (PK/PD, ER, nonclinical, clinical) flows into Module 2 and is translated for multiple agencies. Introduction Regulatory submissions succeed or fail not only on the strength of their data but also on how well the story flows across modules. Reviewers are not reading each report in

The Regulatory Glue: Integrating Modules 2–5 for FDA, EMA, and Beyond Read More »

CTD 2.6.4 Playbook: Writing a Reviewer-Ready Nonclinical ADME That Bridges Module 4 to 2.7.1 (with Modality-Specific Examples)

CTD-series /

Module 2.6.4 is the reviewer’s fast path to your nonclinical ADME story. Done well, it shows what was studied, what was learned, and why those data are sufficient for the current stage of development and the proposed clinical plan, with traceability back to Module 4 and forward to the clinical overview (2.7.1) [1]. What belongs

CTD 2.6.4 Playbook: Writing a Reviewer-Ready Nonclinical ADME That Bridges Module 4 to 2.7.1 (with Modality-Specific Examples) Read More »

From Bioanalysis to Biowaivers: Writing Module 2.7.1 That Travels From IND to NDA

CTD-series /

Executive Snapshot Purpose of 2.7.1: Turn biopharmaceutics and bioanalysis into decision-grade summaries that support clinical interpretation, bridging, and labeling. Keep it living from IND → EoP2 → NDA so the story is traceable and consistent across the dossier [1]. Scope (in brief): BA/BE including food effect, dissolution/IVIVC/BCS, and clinical PK assay summaries (LLOQ/ULOQ, A/P, stability,

From Bioanalysis to Biowaivers: Writing Module 2.7.1 That Travels From IND to NDA Read More »

Artificial Intelligence in Pharmacometrics: Current Applications and Practical Examples

Uncategorized /

1. Introduction Pharmacometrics underpins model-informed drug development through population PK/PD modeling, exposure–response analyses, and PBPK/QSP frameworks. Increasing dataset complexity, adaptive trial designs, and demand for faster timelines are reshaping expectations. AI and ML methods are gaining traction not as replacements, but as accelerators and enhancers. This review presents recent (2022–2025) advancements in AI’s role across

Artificial Intelligence in Pharmacometrics: Current Applications and Practical Examples Read More »